.Pharmacolibrary.Drugs.S_SensoryOrgans.S01A_Antiinfectives.S01AA21_Amikacin.Amikacin

Information

Amikacin is an aminoglycoside antibiotic used primarily in the treatment of severe Gram-negative bacterial infections, including those caused by multidrug-resistant strains. It is administered parenterally, as oral absorption is negligible. Amikacin is approved and still widely used in clinical practice, especially in hospital settings.

Pharmacokinetics

Pharmacokinetic parameters reported for adult patients with normal renal function after intravenous administration.

References

1. Severino, N, et al., & Paredes, N (2023). Population pharmacokinetics of amikacin in suspected cases of neonatal sepsis. British journal of clinical pharmacology 89(7) 2254–2262. DOI:10.1111/bcp.15697 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36811146

2. Medellín-Garibay, SE, et al., & García, B (2022). Amikacin pharmacokinetics in elderly patients with severe infections. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 175 106219–None. DOI:10.1016/j.ejps.2022.106219 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35618200

3. Bressolle, F, et al., & Gomeni, R (1996). Population pharmacokinetics of amikacin in critically ill patients. Antimicrobial agents and chemotherapy 40(7) 1682–1689. DOI:10.1128/AAC.40.7.1682 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8807062

Revisions

• 06/2025 initial generated model